Lung cancer and pleural mesothelioma are two of the most deadly forms of cancer. The prognosis of lung cancer and mesothelioma is extremely poor due to limited treatment modalities and lack of understanding of the disease mechanisms. We have identified mesothelin as a potentially unique therapeutic target that as a specific advantage appears nonessential in most cell types. Mesothelin (MSLN), a plasma membrane differentiation antigen, is expressed at a high level in many human solid tumors, including 70% of lung cancer and nearly all mesotheliomas. However, the role of MSLN in the disease process and underlying mechanisms is largely unknown.
ShRNA knockdown and overexpression of MSLN were performed in human cancer cell lines and corresponding normal cells, respectively. Tumorigenic and metastatic effects of MSLN were examined by tumor sphere formation, migration, and invasion assays in vitro, as well as xenograft tumor assay in vivo. EMT and CSCs were detected by qPCR array, immunoblotting and flow cytometry.
MSLN plays a key role in controlling epithelial-to-mesenchymal transition (EMT) and stem properties of human lung cancer and mesothelioma cells that control their tumorigenicity and metastatic potential. Firstly, MSLN was found to be highly upregulated in non-small cell lung cancer (NSCLC) patient tissues and in lung carcinoma and mesothelioma cell lines. Secondly, genetic knockdown of MSLN significantly reduced anchorage-independent cell growth, tumor sphere formation, cell adhesion, migration and invasion in vitro, as well as tumor formation and metastasis in vivo. Thirdly, ectopic overexpression of MSLN induced the malignant phenotype of non-cancerous cells, supporting its role as an oncogene. Finally, mechanistic studies revealed that knockdown of MSLN reversed EMT and attenuated stem cell properties, in addition to inhibiting tumor growth and metastasis.
These results indicate an essential role of MSLN in controlling EMT and stem cell properties of human lung cancer and mesothelioma cells. Since EMT is an important process in tumor progression and metastasis, and MSLN is nonessential in most normal tissue, our findings on MSLN may provide new insights into the disease mechanisms and may aid in the development of novel targeted therapy for lung cancer and mesothelioma.
Sugarbaker DJ. Multimodality management of malignant pleural mesothelioma: Introduction. YSTCS. 2009;21:95–6.
Frieden TR, Jaffe HW, Stephens JW, Thacker SB. Morbidity and Mortality Weekly Report Centers for Disease Control and Prevention. MMWR Editorial and Production Staff. MMWR. 2012;61:869–88.
Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Cell Biol. 1996;93:136–40.
Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrm KE, et al. Soluble member(s) of the mesothelin͞megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Med Sci. 1999;96:11531–6.
Lan L, Luo Y, Cui D, Shi B-Y, Deng W, Huo L-L, et al. Epithelial-mesenchymal transition triggers cancer stem cell generation in human thyroid cancer cells. Int J Oncol. 2013;43:113–20. PubMed
Hayashida T, Jinno H, Kitagawa Y, Kitajima M, Hayashida T, Jinno H, et al. Cooperation of cancer stem cell properties and epithelial-mesenchymal transition in the establishment of breast cancer metastasis. J Oncol. 2011;2011:1–7. CrossRef
Sowa G, Sowa G. Novel insights into the role of caveolin-2 in cell- and tissue-specific signaling and function. Biochem Res. 2011;2011:1–9. CrossRef
Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res. 2012;1:2478–89. CrossRef
Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011;13(R59):1–11.
Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee B-N, et al. Molecular medicine in practice epithelial–mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Cancer Ther. 2012;11:2526–34. CrossRef
Morata-Tarifa C, Jiménez G, García MA, Entrena JM, Griñán-Lisón C, Aguilera M, et al. Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells. Sci Rep. 2016;6:1–13. e18772. CrossRef
Je. The role of transcription factor TWIST in cancer cells. J Genet Syndr Gene Ther. 2013;4:1–7.
- Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells
Cerasela Zoica Dinu
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II